ITL today announces a new initiative from its Bangkok research center targeting advanced liver cancer.

This new initiate has been made possible and is a result of our earlier announced manufacturing and business model breakthroughs which enable us to produce our products at high profit margins with unprecedented low pricing.
Liver cancer is a major health problem in Asia, with the highest incidence rates in the world. The high incidence is related to the high rates of hepatitis B and hepatitis C in these regions.

Most Asian patients are diagnosed with advanced stage liver cancer. There is only one treatment proven to provide any benefit to advanced liver cancer patients. This is a drug called Sorafenib. Chemotherapy has not demonstrated any benefit for these patients.

However, due  to the high cost of Sorafenib, only a small fraction of patients that can afford to pay can obtain this drug. The overwhelming majority of patients have no treatment options available.

ITL in collaboration with Khoen Ken Medical Center and Dr Wattana, have established a collaboration to test AlloStim combined with cryoablation, CRCL and radiofrequency ablation techniques to determine the most effective combination. This important study, if it proves the effectiveness of our immunotherapy, will provide a treatment option to hundreds of thousands of Asian patients currently without any option.

Further, the expected low cost and low toxicity of our immunotherapy is expected to save government and private insurance hundreds of millions to billions of dollars in the care of advanced liver cancer patients.



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more